PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
PHXM was delisted on the 8th of March, 2024.
9 hedge funds and large institutions have $374K invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
53% more capital invested
Capital invested by funds: $245K → $374K (+$130K)
13% more funds holding
Funds holding: 8 → 9 (+1)
1.19% less ownership
Funds ownership: 2.39% → 1.2% (-1.2%)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$189K |
| 2 |
Millennium Management
New York
|
+$23.8K |
| 3 |
VF
Virtu Financial
New York
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JFG
Jefferies Financial Group
New York
|
-$189K |
| 2 |
Mariner
Overland Park,
Kansas
|
-$23.6K |
| 3 |
Vanguard Personalized Indexing Management
Oakland,
California
|
-$23.6K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$20.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.25K |
PHXM Hedge Fund Activity: Q1 2023 in Review
9 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q1 2023, worth a combined $374K — up 53% from $245K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new PHXM positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $189K. The largest seller was Jefferies Financial Group, exiting entirely with an estimated $189K sold.
- 9 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q1 2023, up from 8 in Q4 2022.
- Funds reported $374K of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q1 2023, up 53% quarter-over-quarter.
- 2 funds opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q1 2023 and 1 closed out, a net change of +1 holder.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q1 2023 was Ikarian Capital, an estimated $189K added.
- The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q1 2023 was Jefferies Financial Group, an estimated $189K sold.
Based on aggregated 13F filings for Q1 2023.